Xynomic Pharmaceuticals Holdings Inc represents a strong commitment to innovation and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough oncology treatments to improve patients' lives. With a vision to become a global leader in precision medicine, Xynomic Pharmaceuticals prioritizes research and collaboration to unlock the full potential of targeted therapies. The company's core values include integrity, patient-centricity, and scientific rigor. By combining cutting-edge science with a dedication to clinical advancement, Xynomic Pharmaceuticals strives to make a meaningful impact in the field of oncology and bring hope to patients worldwide.

Xynomic Pharmaceuticals Holdings Inc is primarily present in the United States and China.

Xynomic Pharmaceuticals Holdings Inc has achieved significant milestones in its operations. The company successfully completed the Phase 1/2 clinical trials for its lead product candidate, abexinostat, a histone deacetylase inhibitor (HDACi). It has also obtained Fast Track designation from the U.S. FDA for abexinostat in combination with rituximab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Xynomic has received Orphan Drug Designation from the FDA for its other clinical-stage product, XP-102 (bucillamine), for the treatment of patients with non-alcoholic steatohepatitis. The company's achievements highlight its dedication to advancing innovative therapies for better patient outcomes.

Xynomic Pharmaceuticals Holdings Inc has a rich history and background in the pharmaceutical industry. Established in [insert year], the company has dedicated itself to the development of innovative therapies for various diseases. Xynomic Pharmaceuticals focuses on targeting unmet medical needs, prioritizing patient well-being and improved outcomes. With a strong emphasis on research and development, the company has actively pursued collaborations and partnerships to advance its pipeline of potential drugs. As a leader in the industry, Xynomic Pharmaceuticals continues to strive towards delivering breakthrough treatments that positively impact patients' lives.

The main competitors of Xynomic Pharmaceuticals Holdings Inc in the market include established pharmaceutical companies such as Pfizer, Novartis, Roche, and Johnson & Johnson. These multinational companies have a strong presence in the pharmaceutical industry and offer a wide range of therapeutic products and services. Xynomic Pharmaceuticals Holdings Inc competes with these companies by focusing on its innovative drug development pipeline and unique market positioning.

Xynomic Pharmaceuticals Holdings Inc is primarily active in the biopharmaceutical industry.

The business model of Xynomic Pharmaceuticals Holdings Inc is focused on developing innovative cancer treatments. The company aims to identify and license promising drug candidates, and then advance them through clinical trials and regulatory approval processes. Xynomic Pharmaceuticals uses a strategic approach that combines in-house development with collaborations and partnerships to maximize resources and expertise. By targeting unmet medical needs and leveraging its expertise in oncology, Xynomic Pharmaceuticals aims to bring new and effective treatments to patients worldwide.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Xynomic Pharmaceuticals Holdings.

KUV:tä ei voida tällä hetkellä laskea Xynomic Pharmaceuticals Holdings osalta.

AlleAktien Laatuscore Xynomic Pharmaceuticals Holdings on 4/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Xynomic Pharmaceuticals Holdings.

Voitto ei voida tällä hetkellä laskea yritykselle Xynomic Pharmaceuticals Holdings.

Xynomic Pharmaceuticals Holdings Inc is a rising biotech company focused on developing novel therapies for treating various types of cancer. Its business model includes research and development, clinical trials, manufacturing, and distribution of drugs. The company's research and development department is the core of the organization, where experts work on identifying and developing new compounds to combat cancer cells. Clinical trials are conducted to investigate the efficacy and safety of promising drug candidates in humans. Manufacturing involves producing the drug once clinical trials are successfully completed, often in collaboration with external partners. Xynomic Pharmaceuticals currently does not have any drugs on the market but plans to seek FDA approval in the near future. The company has several promising drug candidates, including Abexinostat, XP-105, and XP-102, which have shown positive results in clinical trials. Overall, Xynomic Pharmaceuticals is an emerging biotech company dedicated to developing innovative cancer medications.

Xynomic Pharmaceuticals Holdings maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Xynomic Pharmaceuticals Holdings:lle tai yhtiö ei maksa osinkoa.

Xynomic Pharmaceuticals Holdings:n ISIN on US98421X1028.

Xynomic Pharmaceuticals Holdings:n tunnus on XYNO.

Viimeisen 12 kuukauden aikana Xynomic Pharmaceuticals Holdings maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Xynomic Pharmaceuticals Holdings maksanee ennusteiden mukaan 0 USD osingon.

Xynomic Pharmaceuticals Holdings:n tämänhetkinen osinkotuotto on .

Xynomic Pharmaceuticals Holdings maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Xynomic Pharmaceuticals Holdings maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Xynomic Pharmaceuticals Holdings kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Xynomic Pharmaceuticals Holdings osingon 30.1.2025, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 30.1.2025.

Viimeisin osinko maksettiin 30.1.2025.

Vuonna 2024 Xynomic Pharmaceuticals Holdings maksoi 0 USD osinkoina.

Xynomic Pharmaceuticals Holdings:n osingot maksetaan USDssa.